Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical actionability enhanced through deep targeted sequencing of solid tumors.
Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Chen K, et al. Among authors: moulder s. Clin Chem. 2015 Mar;61(3):544-53. doi: 10.1373/clinchem.2014.231100. Epub 2015 Jan 27. Clin Chem. 2015. PMID: 25626406 Free PMC article.
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. Janku F, et al. Among authors: moulder sl. Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216929 Free PMC article.
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. Janku F, et al. Among authors: moulder sl. Oncotarget. 2012 Dec;3(12):1566-75. doi: 10.18632/oncotarget.716. Oncotarget. 2012. PMID: 23248156 Free PMC article.
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Gonzalez-Angulo AM, et al. Among authors: moulder s. Clin Cancer Res. 2013 Oct 1;19(19):5474-84. doi: 10.1158/1078-0432.CCR-12-3110. Clin Cancer Res. 2013. PMID: 24089446 Free PMC article. Clinical Trial.
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Janku F, et al. Among authors: moulder sl. Cell Rep. 2014 Jan 30;6(2):377-87. doi: 10.1016/j.celrep.2013.12.035. Epub 2014 Jan 16. Cell Rep. 2014. PMID: 24440717 Free PMC article. Clinical Trial.
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. Vasan N, et al. Among authors: moulder s. Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7. Oncologist. 2014. PMID: 24710307 Free PMC article.
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.
Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Wheler JJ, et al. Among authors: moulder s. Oncotarget. 2014 May 15;5(9):2349-54. doi: 10.18632/oncotarget.1946. Oncotarget. 2014. PMID: 24811890 Free PMC article.
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. de Melo Gagliato D, et al. Among authors: moulder s. Clin Breast Cancer. 2014 Dec;14(6):468-74. doi: 10.1016/j.clbc.2014.06.001. Epub 2014 Jun 23. Clin Breast Cancer. 2014. PMID: 25065564 Free PMC article. Clinical Trial.
Gene signature-guided dasatinib therapy in metastatic breast cancer.
Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Pusztai L, et al. Among authors: moulder s. Clin Cancer Res. 2014 Oct 15;20(20):5265-71. doi: 10.1158/1078-0432.CCR-14-0800. Epub 2014 Aug 29. Clin Cancer Res. 2014. PMID: 25172932 Clinical Trial.
158 results